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Abstract
Background: T-cell protein tyrosine phosphatase (TCPTP/TC45) is a ubiquitously expressed intra-cellular non-
receptor protein tyrosine phosphatase involved in the negative regulation of several cancer relevant cellular
signalling pathways. We have previously shown that interaction between the a-cytoplasmic tail of a1b1 integrin
and TCPTP activates TCPTP by disrupting an inhibitory intra-molecular bond in TCPTP. Thus, inhibition of the
regulatory interaction in TCPTP is a desirable strategy for TCPTP activation and attenuation of oncogenic RTK
signalling. However, this is challenging with low molecular weight compounds.
Methods: We developed a high-throughput compatible assay to analyse activity of recombinant TCPTP in vitro.
Using this assay we have screened 64280 small molecules to identify novel agonists for TCPTP. Dose-dependent
response to TCPTP agonist was performed using the in vitro assay. Inhibition effects and specificity of TCPTP
agonists were evaluated using TCPTP expressing and null mouse embryonic fibroblasts. Western blot analysis was
used to evaluate attenuation of PDGFRb and EGFR phosphorylation. Inhibition of VEGF signalling was analysed
with VEGF-induced endothelial cell sprouting assays.
Results: From the screen we identified six TCPTP agonists. Two compounds competed with a1-cytoplasmic
domain for binding to TCPTP, suggesting that they activate TCPTP similar to a1-cyt by disrupting the intra-
molecular bond in TCPTP. Importantly, one of the compounds (spermidine) displayed specificity towards TCPTP in
cells, since TCPTP -/- cells were 43-fold more resistant to the compound than TCPTP expressing cells. This
compound attenuates PDGFRb and VEGFR2 signalling in cells in a TCPTP-dependent manner and functions as a
negative regulator of EGFR phosphorylation in cancer cells.
Conclusions: In this study we showed that small molecules mimicking TCPTP-a1 interaction can be used as TCPTP
agonists. These data provide the first proof-of-concept description of the use of high-throughput screening to
identify small molecule PTP activators that could function as RTK antagonists in cells.
Background
Cellular homeostasis is maintained by the coordinated
actions of kinases and phosphatases. Aberrant activation
of several kinases due to overexpression, amplification
or activating mutations are the underlying causes of
many human pathologies like inflammation and cancer
[1]. Conversely, loss of the negative regulation exerted
by phosphatases may lead to a similar outcome [2]. To
date, many kinase inhibitors have been developed and
several small molecule inhibitors and function blocking
antibodies against receptor tyrosine kinases (RTKs) are
already in clinical use to treat different cancers.
TCPTP is a non-receptor protein tyrosine phosphatase
(PTP) that is expressed in all tissues throughout devel-
opment [3]. There are two splice variants of TCPTP
that vary in their C-terminal sequence. The longer 48
kDa form (TC48) is localized to the ER whereas the 45
kDa form (TC45) is predominantly present in the
nucleus, but it is capable of translocating to the
* Correspondence: johanna.ivaska@vtt.fi
1VTT Technical Research Centre of Finland, Medical Biotechnology, Itainen
Pitkakatu 4B, FIN-20520 Turku, Finland
Mattila et al. BMC Cancer 2010, 10:7
http://www.biomedcentral.com/1471-2407/10/7
© 2010 Mattila et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.cytoplasm in response to mitogenic stimuli or a1b1-
integrin-mediated adhesion to collagen [4-6]. Mice and
humans express the 45 kDa form while the 48 kDa form
has been identified only in humans [7,8]. TCPTP has
been implicated in the negative regulation of several sig-
nalling pathways including epidermal growth factor
receptor EGFR [4], vascular endothelial growth factor
receptor-2 VEGFR2 [9], platelet-derived growth factor
receptor beta PDGFRb [10], signal transducer and acti-
vator of transcription-1 STAT1 [11], STAT3 [12],
STAT6 [13], the insulin receptor [14], colony stimulat-
ing factor 1 signalling [15] and hepatocyte growth factor
receptor Met [5]. In addition, two members of the Janus
family of tyrosine kinases (JAKs), JAK1 and JAK3, func-
tion as TCPTP substrates [16]. TCPTP has recently
been established as a negative regulator of SFK, JAK1
and STAT3 signalling during the cell cycle [17].
Recent data has suggested that the production of reac-
tive oxygen species (ROS) is permissive for signalling by
RTKs in response to stimuli [18]. Apart from this gen-
eral mechanism for inhibition of PTPs, in vivo little is
known about PTP activation in cells. In the case of Src
homology 2-domain containing tyrosine phosphatases 1
and 2 (SHP-1 and SHP-2), binding of the two SH2-
domains to phosphotyrosine motifs results in a confor-
mational change and significant activation of the phos-
phatase [19,20]. In TC45 the positively charged C-
terminus was shown to negatively regulate enzyme
activity and a truncation mutant (TC37) lacking this
region is constitutively active [21]. We have previously
shown that TC45 is activated by a collagen-binding
integrin a1b1. The positively charged short cytoplasmic
tail of a1i n t e g r i n( a1-cyt) selectively interacts with the
N-terminal part of TC45 and activates it in response to
adhesion to collagen via alleviating the autoinhibition by
competing with the TC45 C-terminus for binding to the
N-terminal half of the protein [6].
Compared to kinases, much less progress has been
made in the development of new therapeutics targeting
PTPs. Since PTP-1B has an important role in regulating
insulin signalling, PTP-1B inhibitors targeting the active
site are being developed for treatment of diabetes and
obesity [3,22]. Since many PTPs function as negative
regulators in cancer [2,23], their agonists could be effec-
tive drug targets in oncology. However, this might be
challenging since PTP activation may involve disruption
of protein-protein interactions which are difficult to
break by low molecular weight compounds [24]. In the
case of a1-TCPTP interaction a limited number of
amino acids in the a1-tail are critical for the interaction
[6] making the situation more feasible for targeting with
low molecular weight compounds. In the case of p53-
MDM2 interaction the development of small-molecule
inhibitors has been a success and these compounds
induce apoptosis of cancer cells in vivo [25].
Here we have performed a high-throughput screen
(HTS) with recombinant TCPTP (TC45) to identify
novel activators of the enzyme. We demonstrate that six
structurally distinct compounds are capable of activating
TC45 in vitro and that one of these, spermidine, func-
tions in cells to inhibit proliferation, PDGFRb phosphor-
ylation and VEGF-induced angiogenic sprouting in a
TC45-dependent manner. We also show that spermidine
and mitoxantrone compete with a1-cyt in activating
TC45, suggesting that they function by disrupting the
inhibitory intra-molecular bond in TCPTP. These lead
compounds could be used for rational design of TC45
agonist with improved properties.
Methods
Antibodies, siRNAs and reagents
Antibodies against TCPTP (mAb CF4, Calbiochem; 3E2
from M. Tremblay, McGill University, Canada), EGFR
phosphotyrosine 1068 (Cell Signaling Technology),
PDGFRb phosphotyrosine 1021 (Santa Cruz), and a-
tubulin (Hybridoma Bank) were used. HRP-conjugated
second-stage reagents were used, as appropriate. siRNA
against TCPTP has previously been shown to be specific
to TCPTP and to have identical effects to another
TCPTP-targeting oligo [6]. TCPTP siRNA was from
Ambion and the All Stars negative control siRNA from
Qiagen. Peptides containing the cytoplasmic tails of the
a1o ra2 integrins, the integrin-a1 tail fused to the 11-
amino acid -long TAT peptide, and scrambled TAT
(scrTAT, peptide with the TAT sequence fused to a
scramble sequence of the a1-tail amino acids [6]). pep-
tides were synthesized by Innovagen. EGF was pur-
chased from Sigma, and human recombinant PDGF-BB
from Cell Signaling Technology. Recombinant TCPTP,
its mutants, and the constitutively active TC37 were
produced and purified as GST-fusion proteins in
Escherichia coli and cleaved from the GST using Pre-
Scission according to the manufacturer’si n s t r u c t i o n s
(BD Biosciences). DiFMUP (6,8-difluoro-4-methylumbel-
liferyl phosphate) was purchased from Molecular Probes,
and Cell Titer Blue from Promega. Of the small mole-
cule libraries, Spectrum 2000 was from Microsource
Discovery Systems, LOPAC (Library of Pharmacologi-
cally Active Compounds) 1280 from Sigma, ChemDiv
from ChemDiv Inc., ChemBridge from ChemBridge
Corporation, and Tripos from Tripos International.
Spermidine trihydrochloride, Mitoxantrone, Ruthenium
red, and MDL-26,630-trihydrochloride were also from
Sigma. Compounds N21 and F12 were no longer avail-
able from the library provider and could not be tested
further.
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HeLa cells (ATCC) were maintained in DMEM, 10%
F B S ,2m ML - g l u t a m i n e ,5 %C O 2 .P r i m a r yH U V E C s
were freshly isolated as described [26] and cultured in
EBM2 medium. Only HUVECs passaged ≤ three times
were used in this study. They were transfected with
siRNA duplexes (100 nM) by nucleofection using
Amaxa. Nucleofected HUVECs were harvested for RNA
extraction 4 days post-transfection and TCPTP levels
were analysed with Taqman qRT-PCR to study transfec-
tion efficiency. TCPTP wt (EFM7+/+) and knockout
(EFM4-/-) immortalised mouse embryonic fibroblasts
(kindly provided by M. Tremblay) were cultured in
DMEM, 10% FBS, 2 mM L-glutamine, 5 ug/ml Plasmo-
cin, 5% CO2.
Western blot assays
Serum-starved HeLa cells or mouse embryonic fibro-
blasts were left untreated on plastic, stimulated with 10
μM spermidine for 1 h, or in addition treated with 50
ng/ml EGF or PDGF for 5 or 15 min. Cells were lysed
in Laemmli’s sample buffer and resolved on SDS-PAGE
gels for western blot analysis. Western blot bands were
quantified using digital image analysis and only non-
saturated blots were used. The bands to compare in a
blot were enclosed with equal size boxes and pixel
intensity was quantified using GeneGenius Bioimaging
system and Genetools software (Syngene). Automatic
background correction was used.
Elisa assays
96-well streptavidin plate (Costar) wells were incubated
with TBS containing 2.5 μM a1-cytoplasmic tail (biotin-
WKIGFFKRPLKKKMEK) or buffer alone at +4°C for 3
h. Non-specific binding was blocked with 2% BSA/TBS-
Tween containing 10% FBS overnight at +4°C. Purified
recombinant TC45 (cleaved from GST-TC45 as
described in [6]) alone or in the presence of indicated
concentrations of small molecules, a1-cyt or a2-cyt
peptide (a1 cytoplasmic specific sequence lacking the
conserved domain RPLKKKMEK or a2 cytoplasmic
domain WKLGFFKRKYEMTKNPDEIDETTELSS) was
added to the wells and incubated at room temperature
for 1 hour. After extensive washing, TC45 protein bind-
ing to integrin tail sequences was detected using anti-
TCPTP Ab (CF4) and standard horseradish peroxidase
-based detection.
Phosphatase assays
In the in vitro phosphatase assays with purified protein,
full-length purified TCPTP (TC45, see above) was incu-
bated in phosphatase reaction buffer (25 mM Hepes, 50
mM NaCl, 1 mM DTT) in the presence or absence of
synthetic integrin cytoplasmic tail peptides or the novel
small molecule TCPTP activators as indicated. The sam-
ples were assayed for phosphatase activity in triplicate
using DiFMUP (6,8-difluoro-4-methylumbelliferyl
phosphate; Molecular Probes, Eugene, OR) as a sub-
strate. Sample with only reaction buffer and DiFMUP
(blank) was used as a control.
Sprouting assay
Sprouting assays from spheroids were performed as pre-
viously described [9], and based on the method
described earlier [27]. Briefly, HUVECs were divided
into round-bottomed, non-treated 96-wells (Greiner
Bio-One), 3000 cells per well, in EBM2 medium with
0.25% methyl cellulose (Sigma). After overnight incuba-
tion at +37°C 5 spheroids per treatment were pooled
and resuspended in spheroid medium (40% FBS, 0,5%
methyl cellulose, plain medium). Collagen gel (20 mM
Hepes, 1 × DMEM (Sigma), PureCol collagen (Vitro-
gen)) was added 1:1 to cell suspension and the mix
transferred to 48-wells. After polymerisation, medium
+/- VEGF 50 ng/ml, 200 nM ScrTAT or a1TAT-pep-
tide, and 10 uM spermidine were added. Cumulative
length of the sprouts around spheroids was quantified
using 10× magnification after 24 h incubation.
High-throughput screening
Five small molecule libraries were screened for TCPTP
activators. The library compounds were transferred to
384-well assay plates with a Microlab Star automated
liquid handling workstation (Hamilton Robotics) fitted
with 100-nl 96-channel pintool (V&P Scientific Inc., San
Diego, CA). HTS mode TCPTP dispensation was carried
out using a Multidrop Combi dispenser (Thermo Fisher
Scientific, Waltham, MA), and the plates were incubated
for 10 min. at RT. Background fluorescence was mea-
sured during the TCPTP incubation. DiFMUP was
added using Multidrop and the plates were incubated
for 10 min. at RT. Urea was added to stop the reactions
and fluorescence was measured with EnVision 2101
multilabel plate reader (Wallac Oy, PerkinElmer Life
Sciences and Analytical Sciences, Turku, Finland).
Screening data was analysed and the results normalised
using the B-score method, which decreases assay and
instrumentation specific variation between datapoints
(Brideau et al. 2003) implemented in R, a software
environment for statistical computing. (R Development
Core Team 2008). B-score hits were compared with
background measurement results. Hits in wells having
high background signal were discarded as false positive.
Proliferation assay
TCPTP wt and knockout mouse embryonic fibroblasts
were applied on 384-wells, 1500 cells in 35 μlm e d i u m
(DMEM, 10% FBS, 2 mM L-glutamine) per well. Seven
different compound dilutions were prepared in DMSO of
Spermidine, Mitoxantrone, Ruthenium Red and MDL.
Compounds were added in medium to wells, with 6 repli-
cates of each dilution. The resulting end concentrations of
the compounds in the wells were 100 nM, 1 μM, 10 μM,
30 μM, 100 μM, 300 μM and 1 mM. Sample containing
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incubated for 72 h at 37°C, 5% CO2. Cell Titer Blue was
added to wells and incubated for a further 4 h after which
fluorescence at 560 nm was measured with Envision. Data
analysis was performed using GraphPad Prism software
(GraphPad Software, USA).
Statistical analyses
Statistical analyses were performed using the two-tailed
Student’s t-test. All results are expressed as the mean ±
SEM. Following P-values were used to show statistical
significance: *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Results
New TC45 activators found in small molecule screen
We performed a high-throughput screen to identify
small molecule compounds capable of activating TC45.
Five small molecule libraries, Microsource Spectrum
with 2000 biologically active and structurally diverse
compounds, LOPAC1280 with 1280 pharmaceutically
active compounds, Tripos with 6000 compounds, Chem-
Div with 25000 compounds and ChemBridge with 30000
compounds were screened in an in vitro phosphatase
assay. The assay was based on incubation of purified
recombinant TC45 with a fluorescent phosphatase sub-
strate in the presence or absence of small molecule
compounds. The compounds were printed on 384-well
plates. Compound interference was taken into account
by measuring background fluorescence from plates
which contained the compounds and the reaction mix,
but no TC45. TC45 activity assay was initiated by add-
ing purified phosphatase to the wells and allowing
dephosphorylation of phosphatase substrate DiFMUP to
proceed for 10 minutes. The dephosphorylation reaction
was stopped with urea and the fluorescence measured
using a multilabel plate reader (Fig. 1A). Due to the
autofluorescence of some compounds, the true hits were
revealed by comparing the background and assay fluor-
escence values (Fig. 1B). After removal of false positives,
213 putative TC45 activators were found in the primary
screen (Table 1). Interestingly, many potential inhibitors
(data points with a negative B-score) of TC45 were also
identified in the primary screen, however these were not
followed further in this study. A secondary screen con-
firmed that six of the compounds activated TC45 in a
concentration-dependent manner (Fig. 2A). The mole-
cules capable of activating TC45 in vitro were spermi-
dine trihydrochloride (spermidine), mitoxantrone,
ruthenium red, MDL-26,630-trihydrochloride (indicated
hereafter as MDL), N21 (C15H13N5)a n dF 1 2
(C30H38N4O2), the chemical structures of which are
s h o w ni nF i g .1 C .O u to ft h e s em i t o x a n t r o n ew a sm o s t
potent showing on average a 3.3-fold activation of TC45
which was comparable with the 2.4-fold activation by
a1-cyt, a known activator of TC45 [6]. (Fig. 2B).
Spermidine and mitoxantrone activate TC45 via a
mechanism similar to a1-cyt
More detailed information on the molecular mechanism
governing activation of TC45 is needed to facilitate
rational drug design of activating molecules. Thus, we
investigated the mechanism behind the small molecule
-mediated TC45 activation. Based on our previous
results, integrin a1 cytoplasmic tail residues 1164-1179
interact with the amino-terminal part of TC45 activating
it by alleviating the proposed autoregulatory interaction
between the C- and N-terminus of the protein [6]. Since
a1 cytoplasmic tail is positively charged (RPLKKKMEK)
and also the majority of the identified small molecular
activators of TC45 carry positively charged amine-
groups, we investigated whether the compounds would
compete with a1-cyt for binding of TC45. Purified
recombinant TC45 interacts directly with biotinylated
a1-cyt peptide and the interaction is sensitive to compe-
tition with 11 μM a1-peptide but not a2-peptide (Fig.
2C). Interestingly, spermidine and mitoxantrone com-
peted with the solid-phase bound a1-cyt in a concentra-
tion-dependent manner (Fig. 2D), suggesting that these
compounds unlike MDL and Ruthenium Red activate
TCPTP by binding to the same site as the integrin cyto-
plasmic tail.
Spermidine inhibits serum-induced cell proliferation in a
TC45-dependent manner
The majority of TCPTP activators identified here are
previously described molecules with known cellular tar-
gets other than TC45. Therefore, it was important to
characterize whether they influence cell behaviour in a
TC45-dependent manner. TCPTP is a known negative
regulator of many mitogenic signalling pathways and
acute silencing of TCPTP induces cell proliferation in
cancer cells and alterations in signalling pathways
[9,10,28,29]. To study the TC45-dependency of these
compounds, we tested four of the compounds for their
effect on cell proliferation in TC45 knockout and wt
mouse embryonic fibroblasts. The cells were incubated
with the compounds at indicated concentrations for 72
Table 1 Hit rate of TCPTP activators after removal of
false positives due to compound interference.
Library Compounds Primary
hits
Confirmed
activators
Tripos 6000 5 1
ChemDiv 25000 23 1
ChemBridge 30000 167 0
Microsource
Spectrum
2000 16 2
Sigma Lopac 1280 2 2
Total 64280 213 6
Primary hits were individually picked from the libraries and screened again in
HTS. Reproducing hits were confirmed with different concentrations resulting
in total of six validated TCPTP activators.
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played specificity towards TC45, since TC45 knockout
cells were 43-fold more resistant to the compound than
wt cells, suggesting that the presence of TCPTP makes
the wt cells more sensitive to the drug regarding prolif-
eration (Fig. 3). Since spermidine can be oxidized in
serum-containing culture [30], we cannot rule out the
possibility that the spermidine effect is in fact a function
of a spermidine-derived compound. The other three
compounds did not show specificity towards TCPTP
and either inhibited cell proliferation equally well in
both cell types (ruthenium red and mitoxantrone) or
had no significant effect on proliferation (MDL) at the
investigated concentrations.
Spermidine regulates EGFR and PDGFRb signalling via
TC45
TC45 negatively and site-selectively regulates PDGFRb
phosphorylation [10]. To investigate whether spermidine
could attenuate PDGFRb signalling in a TC45-depen-
dent manner, we used TC45 knockout and wt mouse
embryonic fibroblasts. We studied the phosphorylation
levels of PDGFRb Tyr 1021 in spermidine-treated cells
Figure 1 High-throughput screening. A. Overview of the high-throughput screening method used. Five small molecule libraries, the Spectrum
Collection, LOPAC1280, ChemDiv, ChemBridge and Tripos were screened for TCPTP activators. TCPTP was added to 384-well plates and
background fluorescence was measured to control for compound interference due to autofluorescence. DiFMUP phosphatase substrate was
added, and the reaction was stopped with urea prior to measuring fluorescence with EnVision. Integrin a1-cyt peptide was added as a positive
control to each assay plate. B. Shown are the combined results of all library screens. The data points circled in red represent the 6 confirmed
TCPTP activator hits. Data was normalised using the B-score method. C. The chemical structures of the 6 confirmed TCPTP activator hits.
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the indicated concentrations using recombinant TC45 in a DiFMUP phosphatase assay (mean ± SD; n = 3) (due to limited availability N21 was
tested only with 10 μM). B. Small molecule activators (10 μM) and a1-cyt peptide (10 μM) were compared for their ability to activate TC45
(mean ± SD; n = 3; ***, p < 0.001). C-D. Direct binding of recombinant purified TC45 to biotinylated integrin a1 cytoplasmic tail was analysed
using ELISA assay in the presence or absence of the indicated compounds. C. 11 μM integrin a1 and a2-cytoplasmic domains and D. 1 and 10
μM small molecule compounds were tested for their ability to compete with a1-tail for binding to TC45 (mean ± SD; three parallel
measurements from 2 independent experiments **, p < 0.005 ***, p < 0.001).
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starvation. In line with previous data [10], we observed
that PDGF-BB induced 45 ± 4% higher phosphorylation
of PDGFRb in TC45 knockout cells compared to wt
cells (Fig. 4A, B). Importantly, spermidine was able to
attenuate PDGF-induced PDGFRb phosphorylation by
42 ± 6% in TC45 wt cells whereas no inhibition was
detected in TC45 negative cells (Fig. 4A, C). Therefore,
activation of TC45 with spermidine results in TC45-
dependent negative regulation of a well-characterized
TC45 target in cells.
Previously we have shown that collagen-induced acti-
vation of TC45 by integrin a1b1 attenuates EGFR phos-
phorylation at multiple sites [6]. Since our results with
spermidine implied that it can function as a TC45 acti-
vator in mouse cells, we tested if spermidine would have
an effect on EGFR phosphorylation in human cancer
(HeLa) cells. Treatment of the cells with spermidine was
sufficient to significantly attenuate EGFR
phosphorylation in cells (Fig. 4D, E). The observed
attenuation was similar to the one achieved with TC45
activation by cell-membrane permeable TAT-a1-cyt
peptide in this cell line [6]. Taken together, these data
indicate that spermidine-induced activation of TC45 can
be used to inhibit signalling of TC45 target RTKs like
PDGFRb and EGFR in human and mouse cells.
Endothelial cell sprouting is inhibited by spermidine
Recently we showed that VEGFR2 is under the negative
regulation of TC45 and a1-integrin in endothelial cells
(Mattila et al. 2008). We demonstrated that activation of
TC45 with cell-membrane permeable a1-TAT peptide
significantly reduced the length of the VEGF-induced
sprouts in three-dimensional cultures of HUVECs in a
TC45-dependent manner [9]. Here we tested the effect
of spermidine on VEGF-induced sprout formation in
HUVEC spheroids (Korff, Augustin 1999). Also in this
model spermidine and a1-TAT but not scrTAT (a con-
trol peptide with TAT-sequence fused to a scramble
Figure 3 Dose-dependent responses of TCPTP expressing and null MEFs to TCPTP agonist. Four TC45 activating compounds: spermidine,
ruthenium red, mitoxanthrone; and MDL-26,630-trihydrocloride were tested for their effect on cell proliferation in TCPTP wild-type (O) and
knockout (O) mouse embryonic fibroblasts (MEFs). Wildtype and knockout MEFs were incubated in serum-containing medium in the presence of
the HTS-identified compounds, as indicated for 72 h. Cells were detected with Cell Titer Blue reagent, and the non-linear regression analysis was
done using GraphPad Prism (mean ± SD of 3 experiments with similar results).
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Page 7 of 12Figure 4 Inhibitory effects of spermidine on RTK signalling.A .P D G F - i n d u c e dP D G F R b phosphorylation is inhibited by spermidine in a
TCPTP-dependent manner. Serum-starved TCPTP wt (+/+) and knockout (-/-) MEFs were incubated for 1 h in the presence or absence of
spermidine and stimulated with PDGF as indicated. Cell lysates were resolved on SDS-PAGE and probed for phosphorylation at PDGFRb pY1021.
TCPTP (3E2) and tubulin blots serve as controls for TCPTP expression in wt and KO cells, and loading, respectively. B, C. Quantitation of PDGFRb
pY1021 phosphorylation levels normalized against tubulin in TC45 wt and KO cells (mean ± SEM; n = 2; *, P ≤ 0.05) B. or control- and 10 μM
spermidine-treated cells (mean ± SEM; n = 3; *, P ≤ 0.05) C. following 15 minute PDGF treatment are shown. D. Spermidine attenuates EGF-
induced EGFR signalling. Serum-starved HeLa cells were treated with 10 μM spermidine for 1 h, or left untreated, and stimulated with or without
50 ng/ml EGF for 5 or 15 minutes. Cell lysates were resolved on SDS-PAGE and immunoblotted with phospho-specific EGFR antibody. Tubulin
was used as the loading control. A representative experiment out of three with similar results is shown. E. Quantitation of EGFR pY1068
phosphorylation levels normalized against tubulin in 10 μM spermidine treated and control EGF-stimulated HeLa cells (mean ± SEM; n = 3; *, P ≤
0.05).
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order) were able to significantly inhibit VEGF-induced
sprouting in HUVECs (Fig. 5A, B). The basal sprouting
detected in the absence of VEGF was not affected by
spermidine (Fig. 5A, B). Importantly, the ability of sper-
midine to inhibit VEGF-induced endothelial sprouting
was at least partially dependent on TC45. We used a
previously characterized TC45-specific siRNA that
shows identical effects to another independent siRNA
oligo and does not influence levels of other PTPs like
SHP-2 [6,9]. Silencing of TC45 (Fig. 5D) increased
VEGF-induced sprouting in TC45-silenced cells com-
pared to control cells by 35 ± 7% (Fig. 5C). Further-
more, in TC45-silenced cells spermidine inhibited
VEGF-induced sprouting by 43 ± 5% compared to the
89 ± 3% inhibition by spermidine in control cells. The
somewhat limited effects induced by the TCPTP siRNA
in these experiments are most likely due to moderate
TCPTP silencing achieved in HUVEC (Fig. 5D). These
results demonstrate that in human primary endothelial
cells VEGF-induced sprouting is inhibited by spermidine
and that TC45 expression is required for efficient sper-
midine-mediated inhibition of VEGF signalling.
Discussion
At present, massive efforts are being undertaken to gen-
erate drugs (tyrosine kinase inhibitors, TKIs) that inhibit
RTKs playing a central role in human diseases like can-
cer. Many of the targeted specific therapies have failed
and a growing view is that compounds hitting several
targets at the same time may be more beneficial than
single specificity agents (Fojo 2008). Furthermore, many
patients develop resistance to the clinically used inhibi-
tors, which could be circumvented by targeting the
same pathway via other means. TCPTP is a well-charac-
terized negative regulator of several cancer relevant
RTKs including EGFR [4], cMet [5], PDGFRb [10], Insu-
lin receptor [14], and VEGFR2 [9]. In addition, TCPTP
is an important player in immune cells, suggesting that
activating it might be advantageous also in treating
inflammatory conditions [23,28]. Here we have applied a
large scale HT-screen to identify small molecules cap-
able of activating TCPTP. Our results demonstrate that
one of the compounds, spermidine, is capable of activat-
ing TC45 in vitro. Activation of TC45 with spermidine
attenuates EGFR, PDGFRb and VEGFR2 signalling in
different cell types and models. This suggests that
TCPTP activators could possess the desired capacity of
targeting multiple pathways and circumventing known
acquired resistance mechanisms to TKIs like mutations
in the ATP binding sites of RTKs.
The chemical structures of the small molecule activa-
tors of TC45 are presented in Fig. 1C. They are all dis-
crete entities and the main obvious common feature is
that most of the compounds contain positively charged
amine-groups. Mitoxantrone is a well-known agent used
in chemotherapy. It interferes with both DNA and RNA
and is a potent inhibitor of topoisomerase II [31].
Mitoxantrone is used in treatment of prostate cancer
and acute nonlymphocytic leukemia (ANLL), as well as
multiple sclerosis [32-34]. Therefore, it was not surpris-
ing that its cytotoxic effects were not TC45-dependent
in cells (Fig. 3). However, it was the most potent activa-
tor of TC45 in vitro and this could be due to its long,
rigid and flat structure, which is sufficiently large to
achieve high-affinity binding to TCPTP at a site that
overlaps the a1-cyt binding site. Thus structural infor-
mation from this hit could be useful if TCPTP activators
are to be developed further.
Spermidine is a long, flexible, positively charged
polyamine involved in cellular metabolism [35]. The
fact that spermidine inhibits cell proliferation and
attenuates RTK signalling in a TC45-dependent man-
ner is somewhat surprising, considering that all cells
contain substantial amounts of at least one of the poly-
amines, putrescine, spermidine, and spermine [36].
However, based on our data it is clear that acute treat-
ment with micromolar extracellular spermidine, which
is taken up by an effective transport system and possi-
bly metabolised to spermidine derivatives, is sufficient
to result in activation of TC45 and subsequent nega-
tive regulation of signalling pathways. This would be in
line with a previous report which demonstrated that
spermidine or spermidine related compounds, which
have been derived from spermidine via oxidation, are
cytotoxic to cells with upregulated growth pathways
[30] and previous reports demonstrating spermidine
effects on RTK signaling [37,38]. At present, the direct
interaction between TCPTP and a1-cytoplasmic tail is
the only mechanism of TCPTP activation in cells that
has been characterized in detail [6]. The structure of
spermidine resembles that of a1-cyt in that both con-
tain positively charged amine groups, and this may be
reflected in its ability to trigger cellular responses simi-
lar to a1-TAT peptide (Fig. 5). This is further sup-
ported by our finding that spermidine interacts with
TC45 at overlapping sites. It is obvious that none of
the molecules identified here are suitable therapeutic
agents for the modulation of TCPTP function in
human malignancies. This is mainly due to two rea-
sons. First, the identified compounds have also other
targets in cells. Second, they may present limited
membrane permeability due to a highly ionized nature
and the highly flexible, non-drug-like structures of
some of the compounds. However, they provide impor-
tant structural information and may function as start-
ing points for the development of TCPTP activators in
the future.
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Page 9 of 12Figure 5 Inhibition effects of spermidine on VEGF-induced endothelial cell sprouting. A. HUVEC spheroids embedded in three-dimensional
collagen gel were treated with VEGF (50 ng/ml), 200 nM TAT peptides and 10 μM spermidine as indicated. Spheroids were analyzed after 24 h
with 10× magnification and the cumulative sprout length was quantified using image analysis. Shown is a representative of three similar
experiments (mean ± SEM; n = 4-5 spheroids per treatment; **, p ≤ 0.01). B. Representative images show HUVEC spheroids after 24 h incubation
with the indicated treatments taken with 10× magnification. C. HUVEC spheroid assay performed as in A, but with TCPTP siRNA -treated HUVEC
(mean ± SEM; n = 4-5 spheroids per treatment; *, p ≤ 0.05). D. qRT-PCR quantitation of the TCPTP knockdown in HUVECs used in C.
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To the best of our knowledge similar PTP agonist
screens have not been published and thus the hits add
to the few examples of PTP activating molecules
described thus far [39,40]. In conclusion, the small
molecule TCPTP activators described here improve our
understanding of the molecular mechanism of a1-cyt-
mediated activation of TC45 and can allow rational
design of improved TC45 activators that could become
clinically relevant therapeutics in the future.
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